Prana Thoracic to Accelerate Product Development With $3 Million in Series A Funding

Prana Thoracic has closed a Series A funding extension round. The company initially raised $3 million and received a $3 milion non-dilutive grant, bringing its financing total to $9 million. 
 
Prana Thoracic’s Series A extension round was oversubscribed by 30%, highlighting strong investor confidence and interest in the company’s innovative approach to lung cancer intervention.
 
“We are grateful for the overwhelming support from our investors in this financing round. Their confidence in our mission and plan is motivating,” Prana Thoracic CEO/Co-Founder Joanna Nathan said. “This additional funding will enable us to accelerate our efforts in bringing precision surgical solutions to lung cancer patients worldwide.”
 
The round was supported by new investors cultivate(MD), GenHenn Capital, and Houston Angel Network, with participation from prior lead investor New World Angels. Existing funders include Johnson & Johnson Development Corp, Texas Medical Center Venture Fund, and the Cancer Prevention & Research Institute of Texas (CPRIT).
 
“We are excited to support Prana Thoracic in their mission to improve lung cancer treatment. Their approach has the potential to significantly impact patient outcomes,” said Dr. R. Sean Churchill, managing director of cultivate(MD).
 
“The team has made remarkable progress in developing this novel and minimally invasive technique for lung tissue excision, which has the potential to transform the diagnosis and treatment of early-stage lung cancer,” Prana Thoracic Co-Founder/ Chief Scientific Officer Edward M. Boyle, M.D., stated. “Beyond lung applications, they are pioneering new methods to use this technology for other soft tissues and are actively exploring integration with ablation and robotic systems, aligning with the future direction of these fields.”
 
The additional funds will be used to accelerate product development and enable Prana Thoracic to advance through its clinical and regulatory plans.
 
Prana Thoracic was founded with a vision to transform lung cancer intervention through precision surgical solutions. The Houston-based medtech startup aims to right-size interventions for patients seeking earlier options in managing their disease. Its flagship product, the Prana System, has been meticulously designed to enable image-guided, minimally invasive surgery, conserving healthy tissue and driving personalized treatment plans in a range of conditions including lung cancer.